|
1
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokemeyer C, Bondarenko I, Hartmann JT, de
Braud F, Schuch G, Zubel A, Celik I, Schlichting M and Koralewski
P: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
The OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meropol NJ, Schrag D, Smith TJ, Mulvey TM,
Langdon RM Jr, Blum D, Ubel PA and Schnipper LE: American Society
of Clinical Oncology: American Society of Clinical Oncology
guidance statement: The cost of cancer care. J Clin Oncol.
27:3868–3874. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldstein DA, Chen Q, Ayer T, Howard DH,
Lipscomb J, El-Rayes BF and Flowers CR: First- and second-line
bevacizumab in addition to chemotherapy for metastatic colorectal
cancer: A United States-based cost-effectiveness analysis. J Clin
Oncol. 33:1112–1118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carter HE, Zannino D, Simes R John,
Schofield DJ, Howard K, Zalcberg JR, Price TJ and Tebbutt NC: The
cost effectiveness of bevacizumab when added to capecitabine, with
or without mitomycin-C, in first line treatment of metastatic
colorectal cancer: Results from the Australasian phase III MAX
study. Eur J Cancer. 50:535–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruiz-Millo O, Albert-Mari A, Sendra-Garcia
A and Jimenez-Torres NV: Comparative cost-effectiveness of
bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil
in first-line metastatic colorectal cancer. J Oncol Pharm Pract.
20:341–350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Díaz-Rubio E, Pietrantonio F and de Braud
F: Continuing single-agent bevacizumab as maintenance therapy after
induction XELOX (or FOLFOX) plus bevacizumab in first-line
treatment of metastatic colorectal cancer. Oncologist.
17:1426–1428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rinaldi F, George E and Adler AI: NICE
guidance on cetuximab, bevacizumab, and panitumumab for treatment
of metastatic colorectal cancer after first-line chemotherapy.
Lancet Oncol. 13:233–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tappenden P, Jones R, Paisley S and
Carroll C: The cost-effectiveness of bevacizumab in the first-line
treatment of metastatic colorectal cancer in England and Wales. Eur
J Cancer. 43:2487–2494. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shiroiwa T, Motoo Y and Tsutani K:
Cost-effectiveness analysis of KRAS testing and cetuximab as
last-line therapy for colorectal cancer. Mol Diagn Ther.
14:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwartzberg LS, Rivera F, Karthaus M,
Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A
randomized, multicenter phase II study of panitumumab plus modified
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab
plus mFOLFOX6 in patients with previously untreated, unresectable,
wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol.
32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nomura H, Nagai S, Shinohara T, Iwashita
M, Yajima M and Takatoya S: Compared medical costs of treating
ovarian cancer patients with weekly paclitaxel, carboplatin (TC)
chemotherapy. Gan To Kagaku Ryoho. 34:1091–1094. 2007.(In
Japanese). PubMed/NCBI
|
|
14
|
Inage S, Ise Y, Obayashi M, Katayama S and
Gemma A: Cost-effectiveness analysis comparing carboplatin and
weekly paclitaxel with cisplatin and docetaxel in the treatment of
advanced non-small cell lung carcinoma. Gan To Kagaku Ryoho.
37:2093–2100. 2010.(In Japanese). PubMed/NCBI
|
|
15
|
Kurihara T, Kobayashi M, Kogo M, Yoneyama
K, Ito N, Sunaga T, Konishi K, Imawari M, Tobe T and Kiuchi Y:
Cost-effectiveness analysis of chemotherapy with GEM or S-1 for
patients with non-resectable pancreatic cancer. Gan To Kagaku
Ryoho. 37:659–664. 2010.(In Japanese). PubMed/NCBI
|
|
16
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2014 for treatment of colorectal cancer. Int J Clin
Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pharmaceutical Society, . Insurance drug
encyclopedia. Jiho, Tokyo: Pharmaceutical Society; 2012
|
|
19
|
Kawakami Y: Medical fee points table.
35th. Social Insurance Institute; Tokyo: 2008
|
|
20
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
US Department Of Health And Human
Services, . Common terminology criteria for adverse events (CTCAE)
version 4.0. United States: National Cancer Institute; 2009,
http://www.
acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5X7.pdf
|
|
22
|
Goldstein DA, Ahmad BB, Chen Q, Ayer T,
Howard DH, Lipscomb J, El-Rayes BF and Flowers CR:
Cost-effectiveness analysis of regorafenib for metastatic
colorectal cancer. J Clin Oncol. 33:3727–3732. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Go M, Ikagawa M, Kimura M, Iwai M, Usami
E, Yoshimura T and Yasuda K: Awareness of adverse events and
health-related quality of life in outpatients receiving molecular
targeted drugs for lung cancer patients. J Jpn Soc Hosp Pharm.
51:1462–1466. 2015.(In Japanese).
|
